Senti Biosciences Completes Merger With Dynamics Special Purpose Corp.

CFGI’s Capital Markets team assisted Senti Biosciences, Incorporated (“Senti Bio”) with the completion of its merger with Dynamics Special Purpose Corporation (“DYNS”) (Nasdaq: DYNS), a special purpose acquisition company. The business combination was structured as a reverse recapitalization.

The transaction closed on June 8, 2022 and shares of Senti Bio common stock began trading on the Nasdaq Global Market under the ticker symbol “SNTI” at the opening of trading on June 9, 2022. 

Senti Bio is a biotechnology company developing next-generation cell and gene therapies engineered with gene circuits, which are designed to reprogram cells with biological logic to sense inputs, compute decisions and respond to their respective cellular environments. Senti Bio posts announcements, operational updates, investor information and press releases on its website, www.sentibio.com

The CFGI team was led by David Horn (Capital Markets) and Melanie Kavanagh (Accounting Advisory).

For further information on the transaction, please read Senti Bio’s press release